Can you provide the average price target for NOVOCURE LTD stock?
13 analysts have analysed NVCR and the average price target is 25.72 USD. This implies a price increase of 117.77% is expected in the next year compared to the current price of 11.81.
NOVOCURE LTD (NVCR) Forecast, Price Target & Analyst Ratings
NASDAQ:NVCR • JE00BYSS4X48
Current stock price
11.81 USD
-0.34 (-2.8%)
At close:
11.81 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NOVOCURE LTD (NVCR).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 20, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.50
- Revenue Estimate
- 171.22M
Price Target Details & History
Consensus Price Target and Range
Mean target
$25.72
Upside
+ 117.77%
From current price of $11.81 to mean target of $25.72, Based on 13 analyst forecasts
Low
$13.64
Median
$24.48
High
$49.35
Price Target Revisions
1 Month
4.75%
3 Months
1.15%
Price Target Summary
13 Wall Street analysts provided a forecast for the next 12 months for NVCR. The average price target is 25.72 USD. This implies a price increase of 117.77% is expected in the next year compared to the current price of 11.81.
The average price target has been revised upward by 1.15% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.54%
NVCR was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about NVCR.
In the previous month the buy percentage consensus was at a similar level.
NVCR was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-15 | Wedbush | Reiterate | Neutral -> Neutral |
| 2026-01-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-27 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-07-25 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-07-08 | Ladenburg Thalmann | Initiate | Buy |
| 2025-06-27 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-04-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-04-16 | Wedbush | Maintains | Neutral -> Neutral |
| 2025-04-10 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-02 | Evercore ISI Group | Upgrade | In-Line -> Outperform |
| 2024-12-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-16 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2024-10-01 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-07-26 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-07-26 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-07-02 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-06-04 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 20, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.50
- Revenue Estimate
- 171.22M
- Revenue Q2Q
- 10.47%
- EPS Q2Q
- -60.28%
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
-0.24%
Revenue (3 Months)
-0.31%
EPS (1 Month)
-22.50%
EPS (3 Months)
-31.02%
Next Earnings Summary
NVCR is expected to report earnings on 4/20/2026. The consensus EPS estimate for the next earnings is -0.5 USD and the consensus revenue estimate is 171.22M USD.
The next earnings revenue estimate has been revised downward by 0.31% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 509.338M -5.29% | 605.22M 18.82% | 655.353M 8.28% | 705.96M 7.72% | 753.51M 6.74% | 844.63M 12.09% | 1.552B 83.75% | 1.876B 20.88% | N/A | |
| EBITDA YoY % growth | -221.901M -181.31% | -157.258M 29.13% | -135.35M 13.93% | -98.594M 27.16% | -38.435M 61.02% | -8.311M 78.38% | 590.17M 7,201.11% | 1.188B 101.30% | N/A | |
| EBIT YoY % growth | -232.87M -160.19% | -168.493M 27.65% | -150M 10.98% | -160.799M -7.20% | -116.16M 27.76% | -68.345M 41.16% | 319.87M 568.02% | 520.91M 62.85% | 787.44M 51.17% | |
| Operating Margin | -45.72% | -27.84% | -22.89% | -22.78% | -15.42% | -8.09% | 20.61% | 27.77% | N/A | |
| EPS YoY % growth | -1.95 -121.59% | -1.56 20.00% | -1.22 21.79% | -1.60 -31.26% | -1.28 20.11% | -0.74 42.40% | 2.50 439.10% | 4.89 95.51% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.50 -60.28% | -0.38 -4.35% | -0.37 -11.43% | -0.35 -59.12% | -0.33 34.31% | -0.29 23.97% | -0.23 36.20% | -0.26 27.16% |
| Revenue Q2Q % growth | 171.22M 10.47% | 174.03M 9.59% | 180.09M 7.71% | 182.95M 4.93% | 173.68M 1.44% | 178.35M 2.48% | 187.95M 4.36% | 188.69M 3.14% |
| EBITDA Q2Q % growth | -16.294M 49.46% | -12.956M 58.81% | -2M 92.18% | 31.932M 231.72% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -53.158M -49.47% | -38.679M -1.20% | -40.84M -13.38% | -42.429M -9.09% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
11.76%
EPS Next 5 Year
43.12%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
8.09%
Revenue Next 5 Year
22.91%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
24.89%
EBIT Next 5 Year
56.67%
NOVOCURE LTD / NVCR Forecast FAQ
When does NOVOCURE LTD (NVCR) report earnings?
NOVOCURE LTD (NVCR) will report earnings on 2026-04-20.
Can you provide the consensus estimates for NOVOCURE LTD next earnings?
The consensus EPS estimate for the next earnings of NOVOCURE LTD (NVCR) is -0.5 USD and the consensus revenue estimate is 171.22M USD.
How many analysts cover NOVOCURE LTD (NVCR) stock?
The number of analysts covering NOVOCURE LTD (NVCR) is 13.